Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta DrugsNSE:BETA -1.90%90 Equity-to-Asset is 0.49 as of Mar. 2026, which is 16% below its 10-year median of 0.58. GuruFocus rates NSE:BETA with a GF Score™ of 90/100 and a GF Value™ of ₹2,045.91 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Beta Drugs ranks worse than 66.53% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Beta Drugs's Total Stockholders Equity for the quarter that ended in Mar. 2026 was ₹2,448 Mil. Beta Drugs's Total Assets for the quarter that ended in Mar. 2026 was ₹4,958 Mil.
Therefore, Beta Drugs's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.49.
The historical rank and industry rank for Beta Drugs's Equity-to-Asset or its related term are showing as below:
NSE:BETA'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.26 Med: 0.58 Max: 0.66
Current: 0.49
During the past 13 years, the highest Equity to Asset Ratio of Beta Drugs was 0.66. The lowest was 0.26. And the median was 0.58.
NSE:BETA's Equity-to-Asset is ranked worse than 66.53% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs NSE:BETA: 0.49
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Beta Drugs Equity-to-Asset Related Terms
Beta Drugs Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Beta Drugs's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Beta Drugs's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Beta Drugs's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Drugs (NSE:BETA) has a Equity-to-Asset of 0.49 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Beta Drugs and its competitors. This is 16% below median its historical median of 0.58. Over the past decade, Beta Drugs' Equity-to-Asset has ranged from 0.26 to 0.66. According to the industry distribution chart, Beta Drugs ranks #670 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 66.5%.
Is Beta Drugs' Equity-to-Asset too high?
Beta Drugs' current Equity-to-Asset of 0.49 is 16% below median its 10-year median of 0.58. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 0.66. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Beta Drugs' value of 0.49 is 18.3% below this industry median. Based on the distribution chart, Beta Drugs ranks #670 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Beta Drugs has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beta Drugs ranks #670 out of 1007 companies for Equity-to-Asset. This places Beta Drugs in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Beta Drugs' value of 0.49 is 18.3% below this benchmark. Historically, Beta Drugs' own Equity-to-Asset has ranged from 0.26 to 0.66 over the past decade. While the company's 10-year median is 0.58 vs. the industry median of 0.60, Beta Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beta Drugs's current Equity-to-Asset of 0.49 is 18.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Beta Drugs and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Drugs's current Equity-to-Asset is 0.49, which is 16% below median its own 10-year median of 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,045.91, compared to a current price of ₹2,055.20 — trading 0.5% above its estimated fair value. The current Equity-to-Asset is 0.49, which is 16% below median its 10-year median of 0.58 and 18.3% below the Drug Manufacturers industry median of 0.60. Beta Drugs' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current Equity-to-Asset is 0.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued.
The current stock price of ₹2,055.20 is trading 0.5% above its estimated GF Value™ of ₹2,045.91.
GuruFocus considers Beta Drugs to be Fairly Valued.
Key valuation signals for NSE:BETA:
Equity-to-Asset: 0.49 (16% below median its 10-year median of 0.58)
GF Value™: ₹2,045.91 vs. price of ₹2,055.20 (0.5% above fair value)
Industry Position: 18.3% below the Drug Manufacturers median (#670 of 1007)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
90GF Score
Get the complete analysis for NSE:BETA
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
